00:47 , Jul 27, 2018 |  BC Innovations  |  Product R&D

Syncona’s sister act

With the final pieces of its gene therapy portfolio in place, Syncona Investment Management Ltd. thinks its five “sister companies” are poised to capitalize on recent regulatory and technological advances in gene therapy, and push...
06:03 , Jun 14, 2018 |  BioCentury  |  Finance

Gene therapies in Sync

With the launch of a pair of new start-ups, Syncona Ltd. (LSE:SYNC) has invested in a CNS play and a new ophthalmic approach, bringing the U.K. firm’s gene therapy portfolio to five. Syncona invested $23...
19:41 , Nov 11, 2016 |  BC Week In Review  |  Company News

Wellcome Trust, BACIT, Cancer Research UK deal

Wellcome Trust , London, U.K.  BACIT Ltd. (LSE:BACT), London, U.K.  Cancer Research UK , London, U.K.  Business: Cancer  The Syncona investment arm of the Wellcome Trust and cancer-focused investment firm BACIT proposed a deal in...
18:33 , Nov 11, 2016 |  BioCentury  |  Finance

Going big in Britain

After combining with two cancer-focused funds, U.K. VC Syncona Partners expects to have enough firepower to take an aggressive company-building approach more typical of its U.S. counterparts. Under a deal proposed Nov. 7, BACIT Ltd....
00:55 , Nov 8, 2016 |  BC Extra  |  Financial News

Syncona pooling resources with U.K. cancer investors

The Syncona investment arm of the Wellcome Trust and cancer-focused investment firm BACIT Ltd. (LSE:BACT) proposed a deal in which they would combine to form a publicly traded life sciences investment company with about L1...
07:00 , Oct 10, 2016 |  BioCentury  |  Finance

Portfolio POC

Cancer Research Technology Ltd .'s push to move molecules into the clinic rather than out-license them at very early stages of development has paid its first dividends. Late last month, the Cancer Research Technology Pioneer...
08:00 , Dec 22, 2014 |  BC Week In Review  |  Financial News

CRT Pioneer Fund financial update

CRT Pioneer Fund , Berkhamsted, U.K.   Business: Finance   Date announced: 2014-12-16   Note: Cancer Research Technology, the commercial arm of Cancer Research U.K., received an additional £20 million ($31.4 million) investment from BACIT...
08:00 , Dec 22, 2014 |  BioCentury  |  Finance

Flexible funding for CRT

CRT Pioneer Fund's latest close triples the number of cancer programs the fund can move through development compared with its expectations when it launched two years ago. Last week's £20 million ($31.4 million) investment by...
07:00 , Sep 30, 2013 |  BC Week In Review  |  Company News

BACIT Ltd., Sareum, Cancer Research U.K., Institute of Cancer Research deal

The Cancer Research Technology Pioneer Fund , Sareum and investment company BACIT partnered to co-fund development of a checkpoint kinase 1 (Chk1) inhibitor program. The CRT Pioneer Fund received worldwide rights to the preclinical program...
00:25 , Sep 25, 2013 |  BC Extra  |  Company News

CRT Pioneer Fund, BACIT and Sareum to co-fund cancer compound

The Cancer Research Technology Pioneer Fund, Sareum Holdings plc (LSE:SAR) and investment company BACIT Ltd. (LSE:BACT) partnered to co-fund development of a checkpoint kinase 1 (Chk1) inhibitor program. The CRT Pioneer Fund received worldwide rights...